Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziprasidone augmentation for major depressive disorder with incomplete antidepressant response
ACTRN12607000571471Phase 3Terminated
- Sponsor
- Dr. Nitin Dharwadkar
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ziprasidone in major depressive disorder (MDD), sponsored by Dr. Nitin Dharwadkar. Primary endpoints: Hamilton Depression Rating Scale response and Clinical Global Impression improvement. Started Jan 2008; status: terminated.
02
Drugs
ziprasidone
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12607000571471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000571471.